The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Advances in clinical immunotherapy for gastric cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Kang, Y.-K., Boku, N., Satoh, T., Ryu, M.-H., Chao, Y., Kato, K., Chung, H. C., Chen, J.-S., Muro, K., Kang, W. K., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31827-5 · Cited by 2,252
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V., Landsburg, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,860
Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J.-P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0013 · Cited by 1,784
Kim, S. T., Cristescu, R., Bass, A. J., Kim, K.-M., Odegaard, J. I., Kim, K., Liu, X. Q., Sher, X., Jung, H., Lee, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0101-z · Cited by 1,654
Chemotherapy for advanced gastric cancer
Wagner, A. D., Syn, N. L., Moehler, M., Grothe, W., Yong, W. P., Tai, B.-C., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,299
Shitara, K., Özgüroğlu, M., Bang, Y.-J., Di Bartolomeo, M., Mandalà, M., Ryu, M.-H., Fornaro, L., Olesiński, T., Caglevic, C., Chung, H. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31257-1 · Cited by 1,296
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Das, S., & Johnson, D. B. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0805-8 · Cited by 1,145
Shitara, K., Van Cutsem, E., Bang, Y.-J., Fuchs, C., Wyrwicz, L., Lee, K.-W., Kudaba, I., Garrido, M., Chung, H. C., Lee, J., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.3370 · Cited by 1,141
Muro, K., Chung, H. C., Shankaran, V., Geva, R., Catenacci, D., Gupta, S., Eder, J. P., Golan, T., Le, D. T., Burtness, B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00175-3 · Cited by 1,121
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
Haratani, K., Hayashi, H., Chiba, Y., Kudo, K., Yonesaka, K., Kato, R., Kaneda, H., Hasegawa, Y., Tanaka, K., Takeda, M., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2925 · Cited by 1,003
Derosa, L., Hellmann, M. D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A. J., Arbour, K. C., Chaft, J. E., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy103 · Cited by 908
Fukuoka, S., Hara, H., Takahashi, N., Kojima, T., Kawazoe, A., Asayama, M., Yoshii, T., Kotani, D., Tamura, H., Mikamoto, Y., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03296 · Cited by 890
Glimelius, B., Ekström, K., Hoffman, K., Graf, W., Sjödén, P.-O., Haglund, U., Svensson, C., Enander, L.-K., Linné, T., Sellsröm, H., et al. (1997) · Annals of Oncology · doi:10.1023/a:1008243606668 · Cited by 849
Robbins, P. F., Kassim, S. H., Tran, T. L. N., Crystal, J. S., Morgan, R. A., Feldman, S. A., Yang, J. C., Dudley, M. E., Wunderlich, J. R., Sherry, R. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2708 · Cited by 807
B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
Cohen, A. D., Garfall, A. L., Stadtmauer, E. A., Melenhorst, J. J., Lacey, S. F., Lancaster, E., Vogl, D. T., Weiss, B. M., Dengel, K., Nelson, A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126397 · Cited by 778
Etemadi, A., Safiri, S., Sepanlou, S. G., Ikuta, K., Bisignano, C., Shakeri, R., Amani, M., Fitzmaurice, C., Nixon, M., Abbasi, N., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30328-0 · Cited by 635
Janjigian, Y. Y., Bendell, J., Calvo, E., Kim, J. W., Ascierto, P. A., Sharma, P., Ott, P. A., Peltola, K., Jaeger, D., Evans, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.6212 · Cited by 624
Xu, J., Zhang, Y., Jia, R., Yue, C., Chang, L., Liu, R., Zhang, G., Zhao, C., Zhang, Y., Chen, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2484 · Cited by 498
Shankar, B., Zhang, J., Naqash, A. R., Forde, P. M., Feliciano, J. L., Marrone, K. A., Ettinger, D. S., Hann, C. L., Brahmer, J. R., Ricciuti, B., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.5012 · Cited by 474
Wang, F., Wei, X. L., Wang, F. H., Xu, N., Shen, L., Dai, G. H., Yuan, X. L., Chen, Y., Yang, S. J., Shi, J. H., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz197 · Cited by 455
Cancer incidence and mortality in China, 2015
Zhang, S., Sun, K., Zheng, R., Zeng, H., Wang, S., Chen, R., Wei, W., & He, J. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2020.12.001 · Cited by 389
Sato, K., Akamatsu, H., Murakami, E., Sasaki, S., Kanai, K., Hayata, A., Tokudome, N., Akamatsu, K., Koh, Y., Ueda, H., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.019 · Cited by 377
Janjigian, Y. Y., Maron, S. B., Chatila, W. K., Millang, B., Chavan, S. S., Alterman, C., Chou, J. F., Segal, M. F., Simmons, M. Z., Momtaz, P., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30169-8 · Cited by 362
Peng, Z., Cheng, S., Kou, Y., Wang, Z., Jin, R., Hu, H., Zhang, X., Gong, J.-F., Li, J., Lu, M., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-1014 · Cited by 361
Rugo, H. S., Im, S.-A., Cardoso, F., Cortés, J., Curigliano, G., Musolino, A., Pegram, M. D., Wright, G. S., Saura, C., Escrivá-de-Romaní, S., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.7932 · Cited by 343
Kawazoe, A., Fukuoka, S., Nakamura, Y., Kuboki, Y., Wakabayashi, M., Nomura, S., Mikamoto, Y., Shima, H., Fujishiro, N., Higuchi, T., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30271-0 · Cited by 269
Jiang, H., Shi, Z., Wang, P., Wang, C., Yang, L., Du, G., Zhang, H., Shi, B., Jia, J., Li, Q., et al. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy134 · Cited by 247
Self-citationMoehler, M., Dvorkin, M., Boku, N., Özgüroğlu, M., Ryu, M.-H., Muntean, A. S., Lonardi, S., Nechaeva, M., Bragagnoli, A. C., Coşkun, H. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.00892 · Cited by 229
Canonical and Non-Canonical Wnt Signaling in Immune Cells
Chae, W.-J., & Bothwell, A. L. M. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.08.006 · Cited by 221
Moehler, M., Shitara, K., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Campos Bragagnoli, A., Liu, T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2296 · Cited by 208
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
Panda, A., Mehnert, J. M., Hirshfield, K. M., Riedlinger, G., Damare, S., Saunders, T., Kane, M., Sokol, L., Stein, M. N., Poplin, E., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx213 · Cited by 208
Immunotherapy for hepatocellular carcinoma: Current and future
Johnston, M. P., & Khakoo, S. I. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i24.2977 · Cited by 197
Catenacci, D. V. T., Kang, Y.-K., Park, H., Uronis, H. E., Lee, K.-W., Ng, M. C. H., Enzinger, P. C., Park, S. H., Gold, P. J., Lacy, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30326-0 · Cited by 190
Das, S., Suarez, G., Beswick, E. J., Sierra, J. C., Graham, D. Y., & Reyes, V. E. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.5.3000 · Cited by 184
Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy
Subklewe, M. S., von Bergwelt‐Baildon, M., & Humpe, A. (2019) · Transfusion Medicine and Hemotherapy · doi:10.1159/000496870 · Cited by 176
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Sato, H., Okonogi, N., & Nakano, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01666-1 · Cited by 173
Chung, H. C., Bang, Y.-J., S Fuchs, C., Qin, S.-K., Satoh, T., Shitara, K., Tabernero, J., Van Cutsem, E., Alsina, M., Cao, Z. A., et al. (2021) · Future Oncology · doi:10.2217/fon-2020-0737 · Cited by 165
Derks, S., de Klerk, L. K., Xu, X., Fleitas, T., Liu, K. X., Liu, Y., Dietlein, F., Margolis, C., Chiaravalli, A. M., Da Silva, A. C., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.011 · Cited by 163
Kelly, R. J., Lee, J., Bang, Y., Almhanna, K., Blum-Murphy, M. A., Catenacci, D. V. T., Chung, H. C., Wainberg, Z. A., Gibson, M. K., Lee, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2443 · Cited by 144
Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer
Lv, J., Zhao, R., Wu, D., Zheng, D., Wu, Z., Shi, J., Wei, X., Wu, Q., Long, Y., Lin, S., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0704-y · Cited by 141
Bang, Y., Golan, T., Dahan, L., Fu, S., Moreno, V., Park, K., Geva, R., de Braud, F., Wainberg, Z. A., Reck, M., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.06.007 · Cited by 138
H. pyloriVirulence Factors: Influence on Immune System and Pathology
Kalali, B. N., Mejías‐Luque, R., Javaheri, A., & Gerhard, M. (2014) · Mediators of Inflammation · doi:10.1155/2014/426309 · Cited by 137
Yamashita, K., Iwatsuki, M., Harada, K., Eto, K., Hiyoshi, Y., Ishimoto, T., Nagai, Y., Iwagami, S., Miyamoto, Y., Yoshida, N., et al. (2019) · Gastric Cancer · doi:10.1007/s10120-019-00999-9 · Cited by 136
Xu, J., Bai, Y., Xu, N., Li, E., Wang, B., Wang, J., Li, X., Wang, X., & Yuan, X. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3561 · Cited by 122
Self-citationBoku, N., Satoh, T., Ryu, M., Chao, Y., Kato, K., Chung, H. C., Chen, J., Muro, K., Kang, W. K., Yeh, K., et al. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01173-w · Cited by 119
Song, Y., Tong, C., Wang, Y., Gao, Y., Dai, H., Guo, Y., Zhao, X., Wang, Y., Wang, Z., Han, W., et al. (2017) · Protein & Cell · doi:10.1007/s13238-017-0384-8 · Cited by 115
Zhan, X., Wang, B., Li, Z., Li, J., Wang, H., Chen, L., Jiang, H., Wu, M., Xiao, J., Peng, X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2509 · Cited by 107
Greally, M., Chou, J. F., Chatila, W. K., Margolis, M. L., Capanu, M., Hechtman, J. F., Tuvy, Y., Kundra, R., Daian, F., Ladanyi, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3603 · Cited by 107
Okabe, A., Huang, K. K., Matsusaka, K., Fukuyo, M., Xing, M., Ong, X., Hoshii, T., Usui, G., Seki, M., Mano, Y., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0665-7 · Cited by 107
Kim, M., Pyo, S., Kang, C. H., Lee, C. O., Lee, H. K., Choi, S. U., & Park, C. H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198347 · Cited by 104
Wu, Y.-Y., Lin, C.-W., Cheng, K. S., Lin, C., Ym, W., Lin, I.-T., Chou, Y.-H., & Hsu, P.-N. (2010) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2010.04217.x · Cited by 93
Wainberg, Z. A., Fuchs, C. S., Tabernero, J. M., Shitara, K., Muro, K., Cutsem, E. V., Bang, Y., Chung, H. C., Yamaguchi, K., Varga, E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2980 · Cited by 88
Janjigian, Y. Y., Bendell, J. C., Calvo, E., Kim, J. W., Ascierto, P. A., Sharma, P., Ott, P. A., Bono, P., Jaeger, D., Evans, T. R. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.4010 · Cited by 87
L-Selectin Enhanced T Cells Improve the Efficacy of Cancer Immunotherapy
Watson, H. A., Durairaj, R. R. P., Ohme, J., Alatsatianos, M., Almutairi, H., Mohammed, R. N., Vigar, M. A., Reed, S. G., Paisey, S. J., Marshall, C., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01321 · Cited by 87
CAR-T Cell Therapy—An Overview of Targets in Gastric Cancer
Bębnowska, D., Grywalska, E., Niedźwiedzka‐Rystwej, P., Sosnowska‐Pasiarska, B., Smok-Kalwat, J., Pasiarski, M., Góźdź, S. S., Roliński, J., & Polkowski, W. P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061894 · Cited by 87
Nakajima, T. E., Kadowaki, S., Minashi, K., Nishina, T., Yamanaka, T., Hayashi, Y., Izawa, N., Muro, K., Hironaka, S., Kajiwara, T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3559 · Cited by 82
Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment
Tao, K., He, M. Q., Tao, F., Xu, G., Ye, M., Zheng, Y., & Li, Y. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3670-0 · Cited by 77
Wainberg, Z. A., Enzinger, P. C., Kang, Y.-K., Yamaguchi, K., Qin, S., Lee, K.-W., Oh, S. C., Li, J., Turk, H. M., Teixeira, A. C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.160 · Cited by 76
Bang, Y., Muro, K., Fuchs, C. S., Golan, T., Geva, R., Hara, H., Jalal, S. I., Borg, C., Doi, T., Wainberg, Z. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4012 · Cited by 73
Lü, Z., Chen, H., Li, S., Gong, J., Li, J., Zou, J., Wu, L., Yu, J., Han, W., Sun, H., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000374 · Cited by 71
Self-citationYu, Y., Ma, X., Zhang, Y., Zhang, Y., Ying, J., Zhang, W., Zhong, Q., Zhou, A., & Zeng, Y. (2019) · Journal of Cancer · doi:10.7150/jca.31755 · Cited by 68
Hou, J., Ye, J. C., Pu, J. J., Liu, H., Ding, W., Zheng, H., & Liu, D. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01077-3 · Cited by 67
Xia, Y., Tian, X., Wang, J., Qiao, D., Liu, X., Liang, X., Liang, W., Ban, D., Chu, J., Yu, J., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.9534 · Cited by 62
Jiang, H., Zheng, Y., Qian, J., Mao, C., Xu, X., Li, N., Cheng, X., Wang, H., Teng, L., Zhou, H., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07251-z · Cited by 61
Jahn, L., Hombrink, P., Hagedoorn, R. S., Kester, M. G. D., van der Steen, D. M., Rodríguez, T. V., Pentcheva‐Hoang, T., de Ru, A. H., Schoonakker, M. P., Meeuwsen, M. H., et al. (2017) · Blood · doi:10.1182/blood-2016-09-737536 · Cited by 60
Ishikawa, H., Imano, M., Shiraishi, O., Yasuda, A., Peng, Y., Shinkai, M., Yasuda, T., Imamoto, H., & Shiozaki, H. (2013) · Gastric Cancer · doi:10.1007/s10120-013-0258-6 · Cited by 55
Moehler, M. H., Choi, Y., Kim, Y. H., Kim, J. W., Bartolomeo, M. D., Ajani, J. A., Yamaguchi, K., Balogh, Á., Kong-Sanchez, M. T., & Bang, Y. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.4011 · Cited by 51
Cancer immunotherapy in clinical practice��the past, present, and future
Goel, G., & Sun, W. (2014) · 癌症:英文版 · doi:10.5732/cjc.014.10123 · Cited by 47
Alcantara, M., du Rusquec, P., & Romano, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777064 · Cited by 45
PSCA is a target of chimeric antigen receptor T cells in gastric cancer
Wu, D., Lv, J., Zhao, R., Wu, Z., Zheng, D., Shi, J., Lin, S., Wang, S., Wu, Q., Long, Y., et al. (2020) · Biomarker Research · doi:10.1186/s40364-020-0183-x · Cited by 44
Rha, S. Y., Lee, C., Kim, H. S., Kang, B., Jung, M., Bae, W. K., Koo, D., Shin, S., Jeung, H., Zang, D. Y., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.3081 · Cited by 39
Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer
Sasaki, A., Nakamura, Y., Togashi, Y., Kuno, H., Hojo, H., Kageyama, S., Nakamura, N., Takashima, K., Kadota, T., Yoda, Y., et al. (2020) · Gastric Cancer · doi:10.1007/s10120-020-01058-4 · Cited by 36
Zhang, K., Peng, Z., Huang, X., et al. (2017) · Journal of Cancer · doi:10.7150/jca.18946 · Cited by 32
Wei, X., Xu, J., Wang, D., Chen, D., Ren, C., Li, J.-N., Wang, F., Wang, F., & Xu, R. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835921988996 · Cited by 31
Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy
Sznol, M., & Melero, I. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.018 · Cited by 29
Dodbiba, L., Teichman, J., Fleet, A., Thai, H., Sun, B., Panchal, D., Patel, D., Tse, A., Chen, Z., Faluyi, O. O., et al. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.8 · Cited by 25
FOXP3 and Its Cofactors as Targets of Immunotherapies
Nagai, Y., Lam, L., Greene, M. I., & Zhang, H. (2019) · Engineering · doi:10.1016/j.eng.2019.01.001 · Cited by 20
Self-citationFormica, V., Morelli, C., Patrikidou, A., Murias, C., Butt, S., Nardecchia, A., Lucchetti, J., Renzi, N., Shiu, K., Roselli, M., et al. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00723-z · Cited by 19
Upper Gastrointestinal Malignancies in 2017: Current Perspectives and Future Approaches
Solomon, B. L., & Garrido‐Laguna, I. (2018) · Future Oncology · doi:10.2217/fon-2017-0597 · Cited by 18
Klempner, S. J., Bendell, J. C., Villaflor, V. M., Tenner, L. L., Stein, S., Naik, G. S., Sirard, C. A., Kagey, M. H., Chaney, M. F., & Strickler, J. H. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.357 · Cited by 18
Zhang, M., Chen, D., Li, S., Chen, L., Qi, Y., & Zhang, C. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01122-5 · Cited by 15
Cited by
Updates on global epidemiology, risk and prognostic factors of gastric cancer
Yang, W.-J., Zhao, H.-P., Yu, Y., Wang, J.-H., Guo, L., Liu, J.-Y., Pu, J., & Lv, J. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i16.2452 · Cited by 513
Liu, R., Wu, J., Guo, H., Yao, W., Li, S., Lu, Y., Jia, Y., Liang, X., Tang, J., & Zhang, H. (2023) · MedComm · doi:10.1002/mco2.292 · Cited by 264
Self-citationLi, Y., Wang, Z., Gao, P., Cao, D., Dong, R., Zhu, M., Fei, Y., Zuo, X., & Cai, J. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05498-9 · Cited by 55
“Blocking of PD-1/ PD-L1 signaling has brought new hope for GC patients [17].”
BackgroundCleavage of CAD by caspase-3 determines the cancer cell fate during chemotherapy
Ma, J., Zhao, J., Zhang, C., Tan, J., Cheng, A., Niu, Z., Lin, Z., Pan, G., Chen, C., Ding, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60144-2 · Cited by 14
Metadata
- Authors
- Li, K., Zhang, A., Li, X., Zhang, H., & Zhao, L.
- Venue
- Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Publisher
- Elsevier BV
- Published
- 2021-12
- Volume
- 1876
- Issue
- 2
- Pages
- 188615
- ISSN
- 0304-419X (ISSN-L)
- OpenAlex
- W3195406213
- Cited by
- 405
- References
- 87
- FWCI
- 24.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.